Working at Seattle Genetics | Glassdoor

Seattle Genetics Overview

Bothell, WA
501 to 1000 employees
Company - Public (SGEN)
Biotech & Pharmaceuticals
$100 to $500 million (USD) per year
Seattle Genetics is the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition to one marketed product, we are advancing a deep product pipeline ... Read more

Mission: Improving the lives of people with cancer through innovative and empowered antibody based therapies.

Company Updates

  • We presented positive phase 3 ALCANZA clinical trial data for cutaneous T-cell #lymphoma w/ @TakedaOncology at #ASH16

  • We’re excited to be at #ASH16 to discuss new research in #Hodgkin #lymphoma, as part of 18 abstracts & 8 oral presentations.

    Seattle Genetics, Inc.: Investors & News : Press Release

    ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

See AllSee All

Seattle Genetics Video

Provided by employer [?]


Seattle Genetics – Why Work For Us?

Advancing Breakthrough Therapies for Cancer

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

First in a New Class of ADCs

The company’s first ADC product ADCETRIS® (brentuximab vedotin) is approved for two indications in more than 55 countries, including the U.S., Canada, Japan and members of the European Union. The approval of ADCETRIS makes it the first in a new class of ADCs.

To expand on the ADCETRIS opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings.

Seattle Genetics is jointly developing ADCETRIS in collaboration with Takeda Pharmaceutical Company. Under the collaboration, Seattle Genetics has full commercialization rights to ADCETRIS in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.

Advancing Our Robust Pipeline

In addition to ADCETRIS, we are advancing a robust ADC product pipeline designed to address the unmet medical needs of people with cancer. Our strong research and development capabilities are our engine for innovation and long-term growth. Seattle Genetics’ ADC technology is also employed by collaborators and, across both internal and collaborator programs, there are more than 25 ADCs in clinical development using our proprietary approach to empowering antibodies.

Seattle Genetics was founded in 1998 and is headquartered in Bothell, Washington, a suburb of Seattle. The company completed an initial public offering in March 2001, and is traded on the Nasdaq Stock Market under the symbol SGEN. We have more than 650 employees throughout the United States, all with a passion for helping people living with cancer.

Improving the lives of people with cancer through innovative and empowered antibody-based therapies.

We have built a strong corporate culture around the values of integrity, scientific excellence, teamwork, innovation and mutual respect. Seattle Genetics embodies an entrepreneurial spirit that advances breakthrough therapies, which is why we are an acknowledged leader today in antibody-drug conjugate technology.


Passion for helping patients
Revolutionizing therapy for people living with cancer

Honesty, respect and trust guide us

Scientific excellence
Premier science empowers our passion

Teamwork & mutual respect
Shared dedication drives successful collaborations

Entrepreneurial spirit advances breakthrough therapies

Great work environment
Commitment and opportunity inspire purposeful contribution

We value integrity, scientific excellence, teamwork, innovation and mutual respect

At Seattle Genetics, we are passionate about positively impacting the lives of people with cancer. Team members bring that enthusiasm to everything we do, striving to attain individual goals while recognizing the power of working collaboratively to realize Seattle Genetics' vision of improving patient outcomes. Put your passion to work at Seattle Genetics.

As a company leading the field in developing antibody-drug conjugates, Seattle Genetics fosters an environment that recognizes the challenges of breaking new ground by creating opportunities for focused intellectual curiosity and professional growth. Our state-of-the art facility gives our team members the resources to succeed. Located in Bothell's Canyon Park area, Seattle Genetics is close to major highways, dining and shopping.

Seattle Genetics provides a competitive compensation and benefits package (including stock options, medical, dental, vision, life and disability insurance, employee stock purchase plan and 401(k) plan).

If you are passionate about bringing the best of yourself to everything you do, Seattle Genetics offers challenges, opportunities and rewards. We want to hear from you!

Living in the Pacific Northwest

With ready access to Puget Sound, lakes and mountains, residents of the Seattle area enjoy skiing, hiking, boating and a world-class trail system for bicycling, running or walking. A robust and diverse cultural scene includes multiple theater, music, dance, art and sports venues, providing access to the best of local, national and international talent. The Pacific Northwest is rich in scientific research and discovery, and home to leading academic and research institutions, including the University of Washington and Fred Hutchinson Cancer Research Center. Proximity to Vancouver, B.C., the San Juan Islands, Portland, Oregon and the Olympic and Cascade Mountains makes it easy to play as hard as you work. At Seattle Genetics, you’ll find a rewarding career in a place you will be proud to call home.

Seattle Genetics Reviews

Rating TrendsRating Trends
Recommend to a friend
Approve of CEO
Seattle Genetics President and CEO Clay B. Siegall
Clay B. Siegall
49 Ratings
  • "Awesome growing company!"

    • Work/Life Balance
    • Culture & Values
    • Career Opportunities
    • Comp & Benefits
    • Senior Management
    Current Employee - Anonymous Employee
    Current Employee - Anonymous Employee
    Positive Outlook
    Approves of CEO

    I have been working at Seattle Genetics full-time


    Embracing new company perks and great internal mentor/network program


    Long commute from downtown Seattle

See All 80 Reviews

Seattle Genetics Photos

Seattle Genetics photo of: Celebrating Blue Friday and the Superbowl Champion Seahawks
Seattle Genetics photo of: Our campus is in a beautiful setting surrounded by trees and walking paths.
Seattle Genetics photo of: Our scientists are advancing breakthrough therapies for cancer.
Seattle Genetics photo of: We develop monoclonal antibodies and ADCs with novel specificities and activities against selected antigen targets.
Seattle Genetics photo of: State-of-the-art labs in several buildings at our Bothell campus.
Seattle Genetics photo of: Employee volunteers at our Take Your Child to Work event.
See All PhotosSee All

Seattle Genetics Interviews



Getting an Interview

Getting an Interview




  1. Helpful (21)  

    Associate Director, Business Development Interview

    Anonymous Interview Candidate in Seattle, WA
    Declined Offer
    Negative Experience
    Easy Interview


    I applied through a recruiter. The process took 3+ months. I interviewed at Seattle Genetics (Seattle, WA) in April 2017.


    The company HR personnel approached me to see if I would be interested in AD position in Business Development since I had necessary expertise that they were looking for. I was informed that they were having trouble getting candidates since it includes move to Seattle and therefore the position was open from long time. I wasn't actively looking for opportunities and at the outset it seemed like a good opportunity so I decided to interview, however, I only found out how wrong I was after finishing the interviews. It all turned out a waste of time and I eventually declined the very good offer (from Compensation perspective) they gave me and would highly recommend everyone to stay away from this company and this position due to its outdated technology, dysfunctional team environment, backward thinking scientific and management team which is not open to newer outside technologies. Its not conducive environment for a BD professional to learn, do deals and make impact

    1) SGEN's ADC technology is outdated and unproven outside of HL with Adcetris. All of their attempts over years have failed in solid tumors and even liquid tumors outside of HL. Additionally, this technology's (MMAE and MMAF) patents are expiring relatively soon, so if SGEN doesn't find other ways to innovate it has no future. Other competitors (DSI, Immunogen and Mersana) are innovating are already ahead of the curve.
    2) Given the outdated ADC technology you would expect the organization (Scientists and Management) to actively look outwards for new technologies to grow their platform. However, I found out during the interviews that Senior Scientists and even management is reluctant to do deals and look at other technologies. Any attempts to bring in new ideas are met with skepticism and held to much higher standards than their own internal pipeline. Being a company led by founder CEO who is married to ADC technology makes it extremely difficult to innovate in such environment and not good place for BD professional who has to constantly try to thread the needle and face potential disappointment on loosing good deals that you bring in after lot of hard work
    3) It was very apparent that the team is inward focus and doesn't want to look outside. There is no strategic planning done at SGEN and scientists including the CEO decide which molecules go ahead and churn more and more ADC molecules in the world of immuno-oncology where they may not be relevant. There is no concerted effort to look at oncology landscape and study the white space to ascertain if developing a molecule would be commercially attractive. However, by their own admission during interviews I learned that they just churn out molecules from targets that they can use and exploit in ADCs with their technology, sure recipe for disaster and subpar returns in long term on the pipeline R&D dollars
    4) The team seemed pretty dysfunctional, one Director in R&D that I spoke to was bad mouthing one of their asset in Phase 3 (33A) and betting that it most likely will fail. I dont know if it was due to territorial/ownership reasons within organization or if it was really true (If true may actually explain their play to acquire late stage asset from Immunomedics which has gone south and resulted in lawsuits). One Dir in Management was very abrasive and was trying to make me fall on my face with constant interruptions, uptight attitude and trying to belittle my experience. I was asked questions like, how would you deal if member of Senior Management were to scream and yell at you. I appreciate the honesty but this is not a work environment I look forward to working in and I was already looking forward to running out of there with such line of questioning
    5) The BD opportunity involved looking for more technology supporting their outdated ADC technology (new linkers etc. ) and support on other matters. The BD team is not as strong with members themselves lacking good understanding of current oncology landscape and science behind them. I was asked multiple times what types of technologies I would look at and they were writing down my responses and their follow-up questions suggested no basic understanding of the current landscape. They recently overpaid for the questionable Unum technology platform and got themselves into lawsuit over Immunomedics deal

    Overall, at outset it seems like good opportunity but would not recommend it since it focuses on enhancing their outdated ADC technology, working in dysfunctional team where everybody is very inwards focused and not receptive to new ideas (this is antithesis of BD role) and questionable future. I regret my decision to go for interview there, it was waste of time but I would never have found out about all these details from outside, so hopefully this is helpful to other candidates.

    Interview Questions

    • What is your style of negotiation?   1 Answer

    Reasons for Declining

    I didnt like the organization, team and the role

See All 39 Interviews

Seattle Genetics Awards & Accolades

  • Technology Fast 500, Deloitte, 2014
  • Technology Fast 500, Deloitte, 2013
  • Most Innovative Growth Companies(6), Forbes, 2011
  • BizCycle Certified Workplace(Silver), Cascade Bicycle Club, 2015
  • Leaders in Health Care(Innovation in Biopharmaceuticals), Seattle Business, 2012
See More

Work at Seattle Genetics? Share Your Experiences

Seattle Genetics
  • Star
  • Star
  • Star
  • Star
  • Star
Click to Rate